We investigated the role of copy number alterations to refine risk stratification in adult Philadelphia chromosome positive (Ph)+ ALL treated with tyrosine kinase inhibitors (TKI) and allogeneic stem cell transplantation (aSCT). 97 Ph+ ALL patients (median age 41 years, range 18-64 years) within the prospective multicenter GMALL studies 06/99 (n=8) and 07/2003 (n=89) were analysed. All patients received TKI and aSCT in first complete remission (CR1). Copy number analysis was performed with SNP arrays and validated by multiplex ligation-dependent probe amplification (MLPA). The frequencies of recurrently deleted genes were: IKZF1, 76%, CDKN2A/2B, 45%, PAX5, 43%, BTG1, 18%, EBF1, 13%, ETV6, 5%, RB, 14%. In univariate analyses, the presence of CDKN2A/2B deletions had a negative impact on all endpoints: overall survival (p=0.023), disease free survival (p=0.012) and remission duration (p=0.036).
Introduction
Philadelphia chromosome positive (Ph+) ALL is characterized by a reciprocal translocation that fuses the ABL1 oncogene on chromosome 9 to a breakpoint cluster region (BCR) on chromosome 22. Ph+ ALL is the largest genetically defined subtype in adult ALL and is traditionally considered the subtype with the worst prognosis.
Substantial improvements in response and long-term survival have been achieved by combining tyrosine kinase inhibitors (TKI) such as Imatinib or Dasatinib with intensive chemotherapy regimen. [1] [2] [3] [4] [5] [6] However, allogeneic stem cell transplantation (aSCT) in first complete remission (CR1) is the only reliable curative post-remission therapy in adults. 7 Following combined treatment strategies with TKIs, cytotoxic chemotherapy and aSCT, long-term disease-free survival ranges from 30 -69%, 4, 5, 8, 9 with transplant-related mortality (TRM) and relapse contributing approximately equally to treatment failure. This heterogeneity of prognosis suggests additional biologic pathomechanisms other than the BCR-ABL driver lesion that have not been systematically determined. This is further exemplified by the differences between adult and pediatric Ph+ ALL, with the majority of children appearing to be cured by combined TKI and chemotherapy, even without aSCT. 10 To this end, microarray-based genome-wide profiling studies have revealed numerous submicroscopic genetic lesions in patients with BCR-ABL negative as well as Ph+ ALL. The prognostic relevance of these alterations have been studied extensively in pediatric and to a lesser degree in adult ALL. [11] [12] [13] [14] [15] Most recurring genomic abnormalities involve single genes, which are implicated in B-cell differentiation, cell survival, or cell-cycle progression, such as CDKN2A/2B, IKZF1, PAX5, ETV6, RB1, BTG1, EBF1, and therefore have been suggested to play a role in leukemogenesis. Deletions of IKZF1, which encodes the lymphoid transcription factor Ikaros, and of CDKN2A/2B and PAX5
genes have received particular attention due to their high frequency particularly in Ph+ ALL. IKZF1 deletions have been linked to an inferior outcome in most pediatric ALL studies [16] [17] [18] as well as in studies involving adult and adolescent Ph negative BCP-ALL 19 and adult Ph+ ALL, 12 respectively. However, because these associations with prognosis were significant only in univariate but not in multivariate analyses in several initial studies, the additional prognostic value of IKZF1 deletions has been debated. 20, 21 Nevertheless, also subsequent investigations taking into account leukemia subtype and therapeutic context have retained IKZF1 deletions as an unfavourable prognostic marker.
22,23
The prognostic relevance of IKZF1, CDKN2A/2B, PAX5 and other recurrent genomic aberrations in the setting of allogeneic SCT for adult patients with Ph+ ALL has hardly been examined. To this end, in adult Ph+ ALL, the presence of additional cytogenetic lesions in adult Ph+ ALL patients was shown to negatively influence prognosis in the therapeutic setting of TKI combined with chemotherapy 24 or even beyond aSCT.
25
Furthermore, TKI resistance in this patient group has been linked to ABL1 kinase mutations and/or the presence of genomic deletions such as IKZF1 or CDKN2A/2B. 26,27 Kim et al. recently investigated the prognostic relevance of IKZF1 deletions in adult Ph+ ALL patients in a uniform aSCT setting and combined treatment with Imatinib. There, the investigators could show a trend for higher incidence of relapse in patients with IKZF1 deletions, albeit not reaching significance nor independent statistical power in multivariate analyses. 28 We therefore addressed the question whether in adult Ph+ ALL the putative adverse prognosis conferred by IKZF1
and/or other frequent microdeletions of genes associated with B-cell development can be overcome by aSCT, and whether these genomic alterations are predictive of outcome independently of, or in addition to, levels of minimal residual disease (MRD) during front-line therapy. By SNP microarray analysis and validation with multiplex ligation-dependent probe amplification (MLPA), we examined adult Ph+ ALL samples obtained at initial diagnosis from n=97 patients who received Imatinib as part of their treatment and underwent aSCT in CR1, and correlated the genomic data with outcome after aSCT.
Patients and Methods

Patients
The molecular and clinical outcome analyses in this study were carried out retrospectively on bone marrow (n=61) or peripheral blood (n=35), unknown (n=1) Briefly, all patients in the current study received an identical backbone of chemotherapy consisting of a pre-phase with Dexamethasone and Cyclophosphamide, followed by induction chemotherapies consisting of induction phase 1 (=IP1, weeks 1 to 3, containing Dexamethasone, Vincristine, Daunorubicine and PEG-Asparaginase) followed by induction phase 2 (=IP2, weeks 4 to 6, containing Cyclophosphamide, 
Single nucleotide polymorphism microarray (SNP-A) analysis
500 ng of genomic DNA per sample from leukemic blasts were processed according to the Genome Wide Human SNP 6.0 Array protocol (Affymetrix, Santa Clara, CA).
Genotyping files were imported into the CNAG 3.3 software to perform allele-specific copy number analysis with anonymous references as previously described. 
Analysis of minimal residual disease and BCR-ABL mutations
Analysis of MRD was performed using quantitative real-time polymerase chain reaction (qRT-PCR) analysis and confirmatory testing by nested PCR as previously described. 32, 33 Briefly, peripheral blood and bone marrow mononuclear cells (MNC)
were separated by Ficoll centrifugation. Total RNA was extracted with RNA Bee (Ambion, Invitrogen, Darmstadt, Germany) or RNeasy (Qiagen, Hilden, Germany).
cDNA was synthesized from 1-5µg RNA using MMLV (Promega, Mannheim, Germany) and random hexamers (Applied Biosystems, Darmstadt, Germany).
Realtime PCR was performed with the Europe Against Cancer (EAC) 34 primer and probe set for BCR-ABL and ABL1. For samples earlier than 2004, in-house primers were used for GAPDH and BCR-ABL as described previously. 35 ABL1 or GAPDH were used as housekeeping genes. Complete Molecular Response (CMR) was defined as BCR-ABL/ABL ratio below or equal to 10 -4 or a BCR-ABL/GAPDH ratio below or equal to 10 -6
. Historically, the difference of threshold for GAPDH was defined due to the higher intrinsic expression of this gene by approximately 2 log. 36 Major Molecular Response (MMR) for BCR-ABL/ABL was defined as >10 -4 but below 10 -3 or BCR-ABL/GAPDH >10 -6 but below 10 -5 , "no MMR" was defined as >10 -3 for BCR-ABL/ABL and > 10 -5 for BCR-ABL/GAPDH. For calling negative MRD, the ABL copy number had to be at least 10 4 and GAPDH had to be at least 10 6 . MRD evaluation was performed at least once after consolidation for 69 pts. Another 9 patients were evaluated before consolidation. In two patients only FISH results were available.
These were added to the group "no MMR", because they were FISH positive.
Statistical analyses
Relapse was defined by recurrence of more than 5% lymphoblasts in the bone marrow The results of the combined genomic analysis of the seven most commonly deleted genes IKZF1, CDKN2A/2B, PAX5, BTG1, EBF1, ETV6 and RB1 were used to analyse their relationship to clinical outcome of the adult Ph+ ALL patients in the aSCT setting.
Univariate analysis revealed that genomic deletions of CDKN2A/2B were significantly associated with an inferior performance in all three endpoints OS, DFS and REM (OS:
p=0.023, DFS: p=0.012, REM: p=0.036, Figure 1A-C) . The presence of IKZF1 deletions was associated with a trend for higher risk in OS and with significantly inferior outcome for DFS (p=0.045) and REM (p=0.03), (Figure 1D -F) . Similarly, presence of deletions of all other above described commonly deleted genes mostly showed trends for worse performance in all three endpoints. Statistical significance was reached for BTG1 deletions for DFS (p=0.037) and REM (p=0.003) (Supplemental Figures   1A-3C ).
Co-occurrence of common deletions but not the presence of exclusive IKZF1 deletions alone is associated with inferior outcome
Our analysis showed that most patients (61%) had more than one of the recurrently deleted genes affected in the genomes of their leukemia cells. We therefore analysed the clinical outcome data in dependency of the number of deletions of the seven most recurrently deleted genes IKZF1, CDKN2A/2B, PAX5, BTG1, EBF1, ETV6 and RB. As depicted in Figure 2A , n=14 patients had none of these lesions, n=24 had one of the above deletions, n=16 had two, n=25 had three, n=15 had four, n=3 had 5 or more co-occurring common deletions. Increasing numbers of co-occurring recurrent deletions per se were significantly associated with an increased risk of events after aSCT (p=0.011) ( Figure 2B ). When dichotomized into two groups of patients with either 0 or one recurrent deletion versus 2 or more recurrent deletions, the latter group had a substantially worse outcome in all endpoints OS (p=0.018), DFS (p=0.0026) and REM (p=0.0017) (Figures 2C-E) . Interestingly, this was also reflected in significantly higher numbers of leucocytes in the group with two or more recurrent deletions (p=0.0074) ( Figure 2F ). In the light of these results we also asked whether a putative negative effect of IKZF1 deletions was influenced by the presence of accompanying lesions. This analysis showed that patients, who had IKZF1 deletions as an exclusive lesion out of the seven above described recurrent deletions had a significantly better Risk stratification in adult ALL has so far been carried out with clinical parameters such as age, leucocyte counts at initial diagnosis, immunophenotypic ALL subtype but also cytogenetic markers such as the t(9;22), t(4;11), other translocations or numeric chromosomal aberrations. 37, 38 Moreover, the time to reach CR after the initial induction chemotherapy has proven to be prognostically relevant. 39 Expectedly, failure to reach CR after IP1 was highly predictive for relapse, DFS (p=0.008), REM (p<0.0001) (Supplemental Figure 3D-E) . On the transcript level, highly sensitive and standardized detection of minimal residual disease (MRD) by molecular measurement of BCR-ABL fusion products in Ph+ ALL has evolved as an important prognostic tool to determine how quickly patients reach complete molecular remissions (MRD < 10 -4 )
after the first induction therapy (IP1). 32, 39, 40 In our cohort, MRD data pre SCT was available for n=78 patients and MRD response was not significantly associated with outcome regarding any of the tested endpoints (Supplemental Figure 4A- 
C).
Previous data had shown that addition of Imatinib to the treatment protocols of Ph+ ALL improved the outcome. 6 Additionally, an earlier start of Imatinib within the protocol was associated with a higher benefit as compared to a later start of Imatinib therapy. 6 In the cohort of this current study, all patients achieved complete remission after IP2
following treatment with Imatinib. In this context, starting Imatinib early simultaneously with IP1 led to significantly improved outcome for all endpoints, OS (p=0.024), DFS (p=0.0007) and REM (p=<0.0001) (Figure 4A-C) . As all patients in this study received aSCT, we also asked the question of whether the intensity of conditioning had an impact on outcome. This analysis revealed that reduced intensity conditioning (RIC) was associated with poorer OS (p=0.029) and DFS (0.019) (Figure 4D-F) .
To test whether the presence of any of the seven recurrent genomic deletions IKZF1, CDKN2A/2B, PAX5, BTG1, EBF1, ETV6, RB or different co-occurrences of these such as in Figure 2C -E had independent prognostic value in comparison to the other clinical co-variables described above, we performed a multivariable analyses using Cox proportional hazards models to assess their independent predictive power for OS, DFS
and REM. This analysis revealed that in addition to strong clinical and therapeutic co-variables such as Imatinib schedule, conditioning intensity and failure to achieve CR after IP1, CDKN2A/2B deletions were retained as independent negative prognostic factors for all endpoints OS (hazard ratio 2.162, p=0.014), DFS (hazard ratio 2.621, p=0.0054) and REM (hazard ratio 4.066, p=0.0061) ( Table 3 ). To further exclude that this independent predictive effect was based on a biased distribution or confounding effects by connection other variables, we correlated presence of CDKN2A/2B deletions with the most relevant other factors described above. Expectedly in accordance with the multivariable analysis, this did not yield any significant associations (Table 4) .
Discussion
In our study, we performed a comprehensive molecular analysis of a highly homogeneous and well annotated patient cohort of adult Ph+ ALL patients. All patients received treatment according to the GMALL protocols with uniform induction and consolidation combined with different schedules of Imatinib followed by aSCT in CR1.
For a full and unbiased molecular analysis we combined a global explorative SNP array copy number analysis with a concomitant validation of the 7 most common recurrent deletions in ALL by MLPA. Our discovery rate of a mean of 8. Nevertheless, these deletions were also detectable upon visual inspection of the SNP array profiles even though they did not reach the threshold amplitude to result in a positive HMM signal. Therefore, our underlying data of the seven most frequent and recurrent CNAs in ALL generated by the combination of SNP array and MLPA analysis in this study is of higher robustness as compared to previous studies, which only employed either one or the other method to determine profiles of CNAs.
Based on this high confidence data, we concentrated on integrating the 7 most common deletions (IKZF1, PAX5, CDKN2A/2B, BTG1, EBF1, ETV6 and RB1) with the clinical outcome results. Thereby, only the presence CDKN2A/2B deletions but not IKZF1 deletions showed to be significantly adverse for all endpoints. On one side, this could possibly be attributed to the higher fraction of patients with IKZF-deletions, 75%
in our cohort versus 50 % in the cohort of Kim et al. 28 and as compared to the frequency of CDKN2A/2B deletions, which were more evenly distributed so that the prognostic value of IKZF1 deletions was weaker than that of CDKN2A/2B deletions.
On the other hand, when considering that 65% of the samples carried more than one of the recurrent deletions simultaneously, IKZF1 deletions had to be interpreted in a cooperative context with other lesions. Samples that exclusively had IKZF1 deletions without any of the other deletions actually had a significantly lower risk for relapse in the group of patients with IKZF1 deletions (Figure 3) . This was also corroborated by the observation that the mere numeric accumulation of any of the above described common deletions seemed to have a significant effect on survival and risk of relapse (Figure 2) . Nevertheless, when subjected to a multivariable analysis in consideration of other prognostic markers, the numeration of genomic deletions alone did not retain statistical independency.
For prediction of relapse, the treatment parameter of late Imatinib administration and failure to achieve CR after IP1 remained the strongest independent negative parameters in this cohort. In contrast, the level of MRD prior to aSCT had no significant impact on any of the outcome measures. While the issue of MRD pre transplant is controversial, with several reports showing that MRD plays a predictive role in Ph+ ALL, 44, 45 our data is in agreement with other prospective studies 8 and the largest retrospective analysis of Ph+ALL to date, 46 which clearly showed that the BCR-ABL1/ABL transcript ratio prior to aSCT had no impact on outcome. These data are also consistent with the results of a prospective study demonstrating that aSCT can override the otherwise adverse effect of elevated MRD. 47 Interestingly, the presence of CDKN2A/2B deletions emerged as the third and only other independent marker for relapse. The result was similar for disease free survival.
There, timing of Imatinib and TBI based conditioning, which in principle was mostly myeloablative (MAC), were strong prognostically relevant co-variables. However, also CDKN2A/2B and BTG1 deletions were retained as independent molecular markers.
For overall survival, the presence of CDKN2A/2B deletions was even the strongest independent adverse risk marker. In comparison to previous studies, this is a novel and somewhat surprising result, as we show for the first time that a molecular marker (genomic deletion) independently supplements or even outperforms established risk stratifiers in Ph+ ALL and this factor is not IKZF1. To this end, our results are largely in agreement with a recent study that revealed the presence of CDKN2A/2B deletions as determined by FISH analysis in a patient cohort of n=135 adult Ph+ ALL patients as a negative predictor for survival and risk of relapse. 27 Arguments possibly explaining an exceptionally strong role of CDKN2A/2B deletions in Ph+ ALL have been shown by functional biologic experiments indicating absence of gene expression from the CDKN2A/2B locus co-operates with the BCR-ABL oncogene to enhance the aggressiveness of the disease by strongly increasing the self-renewal capacity of leukemia cells, increasing clonal turnover and thereby conferring resistance to TKI therapy. [48] [49] [50] Furthermore, our results are also not in disagreement with the study by Kim et al. 28 , where a negative impact of IKZF1 deletions was shown for relapse, which was however not retained in multivariable analysis. Furthermore, in that study, no comparison regarding the prognostic value of IKZF1 deletions in combination with other deletions was made because other lesions were not examined.
In conclusion, in the adult Ph+ ALL cohort assessed in our study, CDKN2A/2B
deletions for the first time emerged as a new strong and independent prognostic marker for predicting risk of relapse and overall survival on the background of TKI treatment and aSCT. In contrast, IKZF1 deletions did not prove to be a suitable marker because their effect was diluted by a dependency on the co-occurrence of other ALL typical genomic lesions. These results highly warrant the further prospective evaluation of ALL typical genomic deletions, especially CDKN2A/2B for risk stratification of adult Ph+ ALL to further improve therapeutical strategies for this high risk patient group. Abbreviations: aSCT = allogeneous stem cell transplantation, CR1 = first complete remission, n.a. = not available, Sib = sibling, UD = unrelated donor, haplo = haploident, PBSCT = peripheral blood derived stem cell transplantation, BM = bone marrow derived stem cell transplantation, TBI = total body irradiation, Cy = Cyclophosphamide, VP16 = Etoposide, CR = complete remission, IP1 = induction phase 1, OS = overall survival, DFS = disease free survival, REM = remission duration. 
